Early treatment with IgM-enriched intravenous immunoglobulin does not mitigate critical illness polyneuropathy and/or myopathy in patients with multiple organ failure and SIRS/sepsis: a prospective, randomized, placebo-controlled, double-blinded trial

INTRODUCTION: Critical illness polyneuropathy and/or myopathy (CIPNM) is a severe complication of critical illness. Retrospective data suggest that early application of IgM-enriched intravenous immunoglobulin (IVIG) may prevent or mitigate CIPNM. Therefore, the primary objective was to assess the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunner, Richard, Rinner, Walter, Haberler, Christine, Kitzberger, Reinhard, Sycha, Thomas, Herkner, Harald, Warszawska, Joanna, Madl, Christian, Holzinger, Ulrike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056097/
https://www.ncbi.nlm.nih.gov/pubmed/24088271
http://dx.doi.org/10.1186/cc13028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056097/
https://www.ncbi.nlm.nih.gov/pubmed/24088271
http://dx.doi.org/10.1186/cc13028

Ejemplares similares